Airway response of children with primary ciliary dyskinesia to exercise and beta2-agonist challenge
- PMID: 9657584
- DOI: 10.1183/09031936.98.11061389
Airway response of children with primary ciliary dyskinesia to exercise and beta2-agonist challenge
Abstract
In primary ciliary dyskinesia (PCD), chest physiotherapy for airway clearance is essential. Exercise and inhaled beta2-agonists can produce bronchodilation thereby augmenting physiotherapy. However, both can also cause bronchoconstriction, and the effects of these stimuli in PCD are not known. In a preliminary study, the mean coefficients of variation for forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and peak expiratory flow rate (PEFR) in children with PCD were determined. They were 5.4%, 4.4% and 8.4%, respectively. Twelve children with PCD and 12 normal children performed pulmonary functions under resting conditions; during and after a validated treadmill exercise test; and before and 15 min after 200 microg of inhaled salbutamol. At baseline, FEV1, FVC, forced mid-expiratory flow (FEF25-75%) and PEFR were significantly reduced in the PCD group compared with the control group. Exercise produced a significant increase in PEFR in the PCD group. There was no significant difference between the groups in response to salbutamol. Within the PCD group, exercise produced a significantly greater increase in PEFR than beta2-agonist therapy. In conclusion, in children with primary ciliary dyskinesia there is evidence of obstructive pulmonary disease. In these children, exercise is a more potent stimulus for bronchodilation than by inhaled beta2-agonists. Enhancement of airway clearance may best be achieved by encouraging patients to exercise before physiotherapy rather than by inhaling beta2-agonists, but the effects of each should be assessed for each individual before instigating treatment.
Similar articles
-
Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.Thorax. 2001 Jul;56(7):529-35. doi: 10.1136/thorax.56.7.529. Thorax. 2001. PMID: 11413351 Free PMC article. Clinical Trial.
-
The effect of regular salbutamol on lung function and bronchial responsiveness in patients with primary ciliary dyskinesia.Chest. 2000 Feb;117(2):427-33. doi: 10.1378/chest.117.2.427. Chest. 2000. PMID: 10669686 Clinical Trial.
-
[Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily].Ugeskr Laeger. 1992 Nov 16;154(47):3325-8. Ugeskr Laeger. 1992. PMID: 1361083 Clinical Trial. Danish.
-
Inhaled beta2-agonists and airway responses to allergen.J Allergy Clin Immunol. 1998 Nov;102(5):S96-9. doi: 10.1016/s0091-6749(98)70038-7. J Allergy Clin Immunol. 1998. PMID: 9819316 Review.
-
Airway Clearance Techniques in Primary Ciliary Dyskinesia: A Systematic Review.P R Health Sci J. 2024 Sep;43(3):119-124. P R Health Sci J. 2024. PMID: 39269762
Cited by
-
Current and Future Treatments in Primary Ciliary Dyskinesia.Int J Mol Sci. 2021 Sep 11;22(18):9834. doi: 10.3390/ijms22189834. Int J Mol Sci. 2021. PMID: 34575997 Free PMC article. Review.
-
Spirometric indices in primary ciliary dyskinesia: systematic review and meta-analysis.ERJ Open Res. 2019 May 10;5(2):00231-2018. doi: 10.1183/23120541.00231-2018. eCollection 2019 Apr. ERJ Open Res. 2019. PMID: 31111042 Free PMC article. Review.
-
[Management of Primary Ciliary Dyskinesia].Pneumologie. 2020 Nov;74(11):750-765. doi: 10.1055/a-1235-1520. Epub 2020 Sep 25. Pneumologie. 2020. PMID: 32977348 Free PMC article. Review. German.
-
Primary ciliary dyskinesia: current state of the art.Arch Dis Child. 2007 Dec;92(12):1136-40. doi: 10.1136/adc.2006.096958. Epub 2007 Jul 18. Arch Dis Child. 2007. PMID: 17634184 Free PMC article. Review.
-
Active video gaming in primary ciliary dyskinesia: a randomized controlled trial.Eur J Pediatr. 2022 Aug;181(8):2891-2900. doi: 10.1007/s00431-022-04490-z. Epub 2022 May 10. Eur J Pediatr. 2022. PMID: 35536410 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources